Noorik Biopharmaceuticals AG
๐จ๐ญSwitzerland
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Private
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.noorik.com
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Noorik Biopharmaceuticals AG
- Target Recruit Count
- 45
- Registration Number
- NCT06256432
- Locations
- ๐ฎ๐ณ
All India Institute of Medical Sciences, New Delhi, Delhi, India
๐ฎ๐ณAster CMI Hospital, Bangalore, Karnataka, India
๐ฎ๐ณGanesh Shankar Vidyarthi Memorial (GSVM) Medical College, Kanpur, Uttar Pradesh, India
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Noorik Biopharmaceuticals AG
- Target Recruit Count
- 88
- Registration Number
- NCT04771000
- Locations
- ๐ช๐ธ
University Hospital 12 de Octubre, Madrid, Spain
๐ช๐ธHospital Universitario San Cecilio, Granada, Comunidad De Andalucia, Spain
๐ช๐ธHospital Universitario Infanta Leonor, Madrid, Spain
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Noorik Biopharmaceuticals AG
- Target Recruit Count
- 19
- Registration Number
- NCT03827200
- Locations
- ๐ช๐ธ
Hospital Clinic Barcelona, Barcelona, Catalunya, Spain
๐ช๐ธHospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain
๐ช๐ธVall d'Hebron University Hospital, Barcelona, Spain
ยฉ Copyright 2024. All Rights Reserved by MedPath